STAT2

STAT2 (Signal Transducer and Activator of Transcription 2) is the obligate type-I interferon–specific STAT. Unlike stat1, which participates in both type-I (IFN-α/β) and type-II (IFN-γ) responses, STAT2 is selectively recruited to the IFN-α/β receptor complex (IFNAR1/IFNAR2) and has no established role in IFN-γ signaling. Its canonical function is to oligomerize with STAT1 and IRF9 into the ISGF3 heterotrimer, which binds IFN-stimulated response elements (ISREs) in target gene promoters and drives the antiviral transcriptional program. In aging contexts, tonic or dysregulated type-I IFN signaling — mediated partly through ISGF3 — contributes to the sterile inflammatory milieu of inflammaging.

Identity

UniProt: P52630 (STAT2_HUMAN)
NCBI Gene: 6773
HGNC: HGNC:11363 (symbol: STAT2)
Ensembl: ENSG00000170581
Mouse ortholog: Stat2 (one-to-one ortholog; functionally conserved)
Length: 851 amino acids (canonical isoform)
Molecular weight: ~113 kDa (referred to as “p113” in older literature)

Domain architecture

STAT2 follows the canonical seven-domain STAT architecture, with notable distinctions from STAT1:

Domain	Residues (approx.)	Function
N-terminal domain (NTD)	1–130	Cooperativity between tandem STAT dimers; head-to-head stacking
Coiled-coil domain (CCD)	131–320	Cytoplasmic scaffolding; IRF9 interaction surface
DNA-binding domain (DBD)	321–490	Contacts DNA within ISGF3; alone has weak sequence preference
Linker domain	491–571	Structural bridge between DBD and SH2
SH2 domain	572–667	Phosphotyrosine recognition; docks onto IFNAR1 pTyr docking site; recruits TYK2 substrate
Transactivation domain (TAD)	720–851	Longest TAD among STATs; mediates coactivator recruitment; essential for ISG induction

The STAT2 TAD is substantially longer than the STAT1 TAD and is required for full transcriptional activation of ISGs even when STAT1 TAD is absent — an important functional asymmetry within ISGF3 ¹.

Activation mechanism

Canonical type-I IFN signaling

IFN-α or IFN-β binds the IFNAR1/IFNAR2 heterodimer at the cell surface.
tyk2 (constitutively associated with IFNAR1) and JAK1 (associated with IFNAR2) are activated by receptor dimerization and trans-phosphorylation.
TYK2 phosphorylates Tyr690 on STAT2; JAK1 phosphorylates Tyr701 on stat1.
Phospho-STAT2 and phospho-STAT1 heterodimerize via reciprocal SH2 domain–pTyr interactions.
The STAT1:STAT2 heterodimer recruits IRF9 (via IRF9’s IAD domain contacting the STAT2 coiled-coil domain) → forms the ISGF3 heterotrimer.
ISGF3 translocates to the nucleus and binds ISREs (consensus: TTTCNNTTTC) → drives transcription of hundreds of interferon-stimulated genes (ISGs) including OAS1, MX1, IFIT1/2/3, RSAD2, and ISG15.

STAT2 does not form homodimers and does not bind IFN-γ–activated sequence (GAS) elements. The ISGF3 specificity for ISRE (vs GAS) is the biochemical basis for STAT2’s type-I IFN restriction ¹.

Unphosphorylated ISGF3 (U-ISGF3)

Even in the absence of active IFN signaling, unphosphorylated STAT1, STAT2, and IRF9 form a low-affinity complex called U-ISGF3. U-ISGF3 drives constitutive, basal-level expression of a subset of ISGs — predominantly those with high-affinity ISREs — and is distinct from the phospho-ISGF3 transcriptional program in kinetics and target-gene repertoire. In aged and senescent cells, U-ISGF3 contributes to ISG overexpression even without exogenous IFN stimulus (see Aging context below) ².

Negative feedback: the STAT2–USP18 axis

STAT2 plays a dual role — it is both a positive effector and a required scaffold for negative feedback. USP18 (a deubiquitylase that removes ISG15 modifications and independently inhibits IFNAR2 signaling) is recruited to IFNAR2 through a constitutive interaction with STAT2, not with the receptor itself. This means:

STAT2 physically bridges USP18 to IFNAR2, dampening subsequent IFN-α signaling.
This feedback acts specifically on IFN-α but not IFN-β (IFN-β uses a distinct receptor configuration that bypasses USP18 blockade), creating a natural desensitization asymmetry.
In STAT2-deficient cells, USP18 cannot localize to IFNAR2, so the negative-feedback loop is absent — yet signaling is also absent because STAT2 is required for forward signaling. This creates a paradox in STAT2 LOF: abrogated signaling, not hyper-signaling ³.

The STAT2 abundance controls pathway gain: mathematical modeling shows STAT2 levels predict IFN-α amplitude, while USP18 abundance controls desensitization kinetics ⁴.

Loss-of-function: Hambleton 2013

The only well-characterized human STAT2 loss-of-function syndrome was reported by Hambleton et al. (2013): a consanguineous pedigree with a homozygous intronic mutation in STAT2 that abolished correct splicing, eliminating STAT2 protein ⁵.

Key clinical features:

Index case: severe vaccine-strain measles pneumonitis following routine MMR immunization (near-fatal).
Sibling: died from an uncharacterized viral infection in infancy.
Surviving STAT2-deficient individuals: otherwise generally healthy with intact adaptive immunity and normal development — suggesting type-I IFN/ISGF3 signaling is not essential for defense against most common childhood pathogens, but is critical for live-attenuated vaccine strains.
Patient fibroblasts showed profoundly permissive viral replication correlated with absent type-I IFN signaling.

This stands in contrast to STAT1 LOF, which causes broader susceptibility to mycobacterial, bacterial, and viral pathogens, reflecting STAT1’s participation in both type-I and type-II IFN arms.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes (LOF syndrome documented)
Replicated in humans?	yes (LOF); gain-of-function/aging-context not studied

Gain-of-function: pseudo-TORCH syndrome 3

STAT2 also features in gain-of-function (GOF) interferonopathies. Homozygous missense mutations at Arg148 (R148Q or R148W; both in the coiled-coil domain) impair USP18 interaction with STAT2, preventing USP18 from localizing to IFNAR2 and exerting negative feedback — the result is constitutively elevated type-I IFN signaling. This mechanism causes pseudo-TORCH syndrome 3 (autosomal recessive; also phenocopied by inherited USP18 deficiency), characterized by neonatal-onset multisystemic inflammation, cerebral calcifications, white matter abnormalities, coagulopathy, and elevated ISG signatures, mimicking congenital TORCH infections without an infectious etiology ⁶⁷. needs-replication — only a small number of affected individuals with STAT2 R148Q/R148W have been described; expanded cohort characterization is needed.

Aging context

STAT2’s connection to aging operates through several mechanisms, all mediated by the broader type-I IFN axis rather than STAT2 in isolation:

1. Tonic IFN signaling and inflammaging

Aged tissues exhibit chronically elevated basal ISG expression — part of the sterile inflammatory milieu called inflammaging. This tonic ISG signature is driven in part by:

cGAS–STING activation by cytosolic DNA (micronuclei, cytoplasmic chromatin fragments, mitochondrial DNA leakage) in senescent cells, producing IFN-β ⁸.
Downstream STAT2-dependent ISGF3 target gene induction contributing to the ISG component of the SASP.

needs-replication — the relative contribution of STAT2 vs. STAT1 vs. IRF9 to the basal ISG component of SASP has not been systematically dissected in primary human aged cells.

2. U-ISGF3 in senescent cells

Yamagami et al. (2018) showed that senescent human fibroblasts display constitutive ISG transcription mediated by unphosphorylated ISGF3 (U-ISGF3) independent of measurable IFN production. This U-ISGF3 activity required the presence of STAT2 (and STAT1 + IRF9) but not Tyr690 phosphorylation, suggesting that protein accumulation — not kinase signaling — can sustain a low-level antiviral-like transcriptional state in aging cells ².

Implication: STAT2 protein levels in senescent cells may be functionally relevant independent of canonical TYK2-mediated phosphorylation — a distinction overlooked in phosphoproteomics studies that key on pTyr690.

3. STAT2 as a specificity determinant: ISGF3 vs. STAT1 homodimer (GAF)

Across a broad aging literature, IFN-γ signaling (mediated by STAT1 homodimers / GAF binding GAS elements) has been more prominently studied in aging than type-I IFN signaling. STAT2’s selective contribution to the ISGF3/ISRE axis means it distinguishes the antiviral ISG program from the pro-inflammatory IFN-γ arm — a distinction with therapeutic relevance. Blocking IFNAR (as with anifrolumab in lupus) abrogates STAT2 signaling specifically, while leaving IFN-γ/STAT1-GAF intact.

needs-human-replication — Whether pharmacological suppression of the ISGF3/STAT2 axis (upstream via TYK2 or IFNAR blockade) reduces inflammaging markers or improves aging phenotypes has not been tested in aged human cohorts. TYK2 inhibitors (e.g., deucravacitinib) approved for psoriasis/lupus offer a translatable tool.

Pathway membership

jak-stat-pathway — STAT2 is the type-I IFN–specific node; activated by tyk2 at IFNAR1
type-i-interferon-signaling — core effector of the antiviral transcriptional response
cgas-sting — upstream source of IFN-β → ISGF3 activation in senescent cells

Key interactors

Interactor	Interaction type	Functional consequence
stat1	Obligate heterodimer (pTyr-SH2)	Forms ISGF3 with IRF9
tyk2	Kinase → substrate (Tyr690)	Activates STAT2 upon IFN-α/β stimulation
IRF9	Non-covalent (coiled-coil contact)	Completes ISGF3; provides ISRE-binding specificity
IFNAR1	Docking (via TYK2 scaffold)	Receptor-proximal activation
IFNAR2	Constitutive (via STAT2 CC+DB domains)	Recruits USP18 for negative feedback ³
USP18	Scaffolding	STAT2 bridges USP18 to IFNAR2; negative-feedback loop

Pharmacology and druggability

Druggability tier: 3 (predicted druggable; no clinical STAT2-direct inhibitor). Upstream modulators exist:

TYK2 inhibitors (deucravacitinib — FDA-approved for psoriasis; selective TYK2 pseudokinase domain) — block Tyr690 phosphorylation, abrogating ISGF3 assembly. Reduce type-I IFN-driven ISG signatures in SLE patients. Not studied in aging.
IFNAR blockade (anifrolumab — FDA-approved for SLE) — abolishes both STAT1 and STAT2 activation at the receptor level. Phenocopies STAT2 LOF for downstream signaling, with the important difference that JAK1/TYK2-independent receptor proximal signaling is also blocked.
JAK1 inhibitors (upadacitinib, filgotinib) — broad JAK inhibition; less STAT2-specific than TYK2i.

Aging-context tier-3 rationale. No clinical drug targeting STAT2 directly for an aging indication exists. TYK2 inhibitors engage the pathway clinically but are approved for autoimmune indications only; no aging-rejuvenation trial has engaged STAT2/TYK2 as a primary endpoint. Tier 3 reflects predicted druggability via upstream kinase modulation. needs-human-replication — testing whether TYK2i reduces tonic ISG burden in aged individuals remains an open experimental question.

Limitations and gaps

#gap/needs-human-replication — STAT2 aging-specific role is inferred from type-I IFN axis biology; no primary studies have examined STAT2 protein levels or activity specifically in aged human cells vs senescent cells vs old mouse tissue.
#gap/no-mechanism — The driver of U-ISGF3 accumulation in senescent cells (vs simple IFN-responsive activation) is not mechanistically resolved; chromatin accessibility changes at ISREs are hypothesized but untested.
#gap/needs-canonical-id — GenAge ID for STAT2: not found in HAGR/GenAge human aging gene set as of 2026-05-13; STAT2 is not a curated aging gene in the canonical sense. Leave genage-id null.
#gap/contradictory-evidence — Whether inflammaging ISG signature is driven primarily by type-I IFN (ISGF3/STAT2-dependent) vs IFN-γ (STAT1-GAF-dependent) vs other cytokines varies by tissue and cohort; current data do not clearly partition the STAT2-specific contribution.
STAT2 phosphoproteomics in aged tissues: no dedicated aging-context datasets available as of this draft. pTyr690 is rarely captured in standard aging proteomics panels.

Footnotes

doi:10.1038/nrm909 · review (Nat Rev Mol Cell Biol) · Levy DE, Darnell JE Jr. · 2002 · conceptual framework for STAT-family domain architecture and ISGF3 specificity; STAT2+STAT6 TADs have ≥10-fold greater stimulatory activity than other STAT TADs · cited-by: 3,151 · archive: local PDF ↩ ↩²
doi:10.1038/s41514-018-0030-6 · in-vitro · model: human NHDFs (normal human dermal fibroblasts) at replicative senescence (passage 23 vs passage 5); Werner syndrome fibroblasts (passage 8) · demonstrated constitutive ISG expression (IFIT3, OASL, ISG15, Mx2, IFI27) via unphosphorylated ISGF3 independent of IFN production; STAT1 and STAT2 knockdown reduced ISG expression and ISRE activity; JAK1 knockdown did not · cited-by: 15 · archive: local PDF ↩ ↩²
doi:10.1038/nsmb.3378 · in-vitro / biochemical · model: human fibrosarcoma 2fTGH-derived U-series cells + murine Stat2-/- MEFs + reconstitution assays · STAT2 bridges USP18 to IFNAR2 via coiled-coil (CC) and DNA-binding (DB) domains (not TAD); negative feedback on JAK1 phosphorylation requires STAT2 physical interaction with USP18 · cited-by: 190 · archive: local PDF ↩ ↩²
doi:10.15252/msb.20198955 · in-silico / in-vitro (ODE mathematical model calibrated to 1,918 data points + validation in primary human hepatocytes from 6 patients) · model: Huh7.5 hepatoma cells + HepG2-hNTCP cells + primary human hepatocytes · basal STAT2 abundance predicts patient-specific IFN-α signal amplitude; basal USP18 abundance determines desensitization threshold · cited-by: 53 · archive: local PDF ↩
doi:10.1073/pnas.1220098110 · n=5 homozygous-affected members identified across pedigree (proband + 4 relatives) · observational/case-series · model: human (homozygous STAT2 c.381+5 G>C splice-site LOF, intron 4); in-vitro patient skin fibroblasts · cited-by: 241 · archive: local PDF ↩
UniProt P52630 (STAT2_HUMAN), variant annotations for R148Q and R148W — curated database entry confirming PTORCH3 disease association and USP18-interaction-loss mechanism. ↩
doi:10.1084/jem.20192151 · PMID: 32092142 · observational/case-report · Gruber C et al. · J Exp Med 2020 · homozygous STAT2 R148Q causes type I interferonopathy by failing to traffic USP18 to IFNAR2; clinical phenocopy of inherited USP18 deficiency · model: human patient + in-vitro patient cells ↩
doi:10.1038/s41467-018-03555-8 · in-vitro + in-vivo (mouse) · model: human TIG-3 fetal lung diploid fibroblasts rendered senescent by serial passage or oncogenic HRasV12; in-vivo: hepatic stellate cells in HFD mouse liver · cGAS-STING activation by cytoplasmic DNA (from downregulated DNase2/TREX1) drives IFN-β → SASP; blocking pathway (siSTING/sicGAS) reduces SASP factor expression · cited-by: 339 · archive: local PDF ↩

🧬 Aging Wiki

Explorer

stat2